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Abstract
The expression of N-cadherin (NCAD) has been shown to correlate with increased tumor cell motility and metastasis.
However, NCAD-mediated adhesion is a robust phenomenon and therefore seems to be inconsistent with the “re-
lease” from intercellular adhesion required for invasion. We show that in themost invasivemelanoma and brain tumor
cells, altered posttranslational processing results in abundant nonadhesive precursor N-cadherin (proNCAD) at the cell
surface, although total NCAD levels remain constant. We demonstrate that aberrantly processed proNCAD promotes
cell migration and invasion in vitro. Furthermore, in human tumor specimens, we find high levels of proNCAD as well,
supporting an overall conclusion that proNCAD and mature NCAD coexist on these tumor cell surfaces and that it is
the ratio between these functionally antagonistic moieties that directly correlates with invasion potential. Our work
provides insight into what may be a widespread mechanism for invasion and metastasis and challenges the current
dogma of the functional roles played by classic cadherins in tumor progression.
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Introduction
During tumor progression, a subset of primary tumor cells undergoes
molecular changes leading to an increased ability to survive, proliferate,
invade, and often form secondary metastases [1,2]. The mechanisms
governing invasion and metastasis are complex and poorly understood.
However, it is recognized that, at the cell surface, alterations in classes
of adhesion molecules are critical for detachment of tumor cells,
mobility through host tissue, and the successful formation of sec-
ondary sites [1,3]. These alterations involve not only reduction in sur-
face adhesion molecules but also changes in the profile of adhesion
molecule expression.
Classic cadherins are key cell adhesion molecules (CAMs) in epithe-
lia that mediate Ca2+-dependent and generally homophilic intercellular
interactions [4,5]. The precursor form of classic cadherins contains a
signal sequence that is cleaved to reveal a prodomain of 130 amino
acids, which lacks the essential structural features for adhesion [6].
This explains why its presence before cleavage protects from intra-
cellular cadherin interactions [4,7,8]. Processing of the prodomain is
necessary to generate functional cadherins at the cell surface [4].
Abbreviations: CAM, cell adhesion molecule; ECAD, E-cadherin; NCAD, N-cadherin;
PC, proprotein convertase; proNCAD, precursor N-cadherin; SCC, squamous cell carci-
noma; VGP, vertical growth phase
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Classic cadherins play important roles in cancer pathogenesis
[3,9,10], and the metastatic potential of tumor cells inversely correlates
with cadherin expression [11–14]. An E-cadherin (ECAD)–to–N-
cadherin (NCAD) switch has also been shown to take place in several
types of carcinomas. For example, in melanoma, malignant vertical
growth phase (VGP) cells lose ECAD expression, whereas NCAD levels
significantly increase [15,16] and persist throughout transformation. In
general, loss of ECAD correlates with high tumor grades and poor prog-
nosis [17,18], and the up-regulation of NCAD correlates with induced
cellular motility [19–21].
How does loss of ECAD and the up-regulation of NCAD promote
tumor cell invasion andmetastasis? Because ECAD functions in “anchor-
ing” normal cells in place [22], the interpretation has been that loss of
ECAD results in the disruption of adhesion junctions between adjacent
cells allowing malignant cells to detach from the “ECAD” epithelial cell
layer and invade the host tissue. The up-regulation of adhesively com-
petent NCAD is thought to mediate adhesion of malignant cells to
NCAD-expressing stromal or endothelial cells, rather than epithelial
cells, facilitating invasion of tumor cells to distant sites [23,24].
Other tumors do not undergo an ECAD-to-NCAD shift but exhibit
persistence of NCAD in their component cells normally, as well as in
the highlymalignant state. An interestingmodel is primary brain tumors,
which arise from cells derived from the primitive neuroepithelium [25].
Glioblastomamultiforme is themost aggressive type ofmalignant glioma
[26]. These tumors invade throughout vital brain regions as single cells,
with a predilection for existing anatomic structures, such as white matter
tracts, the subpial glial space, and the periphery of neurons and blood
vessels, and almost never metastasize outside the brain [27,28]. Glioma
cell invasion depends on complex interactions, and possibly cooperation
with resident brain cells [29–31], and likely correlates with CAM pro-
files. An up-regulation of NCAD in malignant glioma cells compared
with normal brain tissue has been observed [32].
We studied the cellular localization and functional state of cell surface
expressed NCAD in primary glial tumors and during melanoma trans-
formation. Our results demonstrate that in highly invasive glioma cells
and during malignant melanoma transformation, in addition to mature
NCAD, significant amounts of nonadhesive precursor N-cadherin
(proNCAD) are present on the cell surface. It seems that high levels
of surface proNCAD promote detachment, tumor cell migration,
and invasion. Furthermore, we detect high levels of proNCAD ex-
pression in a panel of human primary and metastatic tumors. Mecha-
nistically, we demonstrate that the differential expression of furin, a
common proprotein convertase (PC) enzyme [33] in tumor cells, seems
to be implicated in this phenomenon.
Materials and Methods
Ethics Statement
Humanbrain tumor sampleswere obtained from theMontrealNeuro-
logical Institute Brain Tumor Tissue Bank. The institutional ethics com-
mittee approved all experimental procedures carried out on human tissue.
Melanoma, breast, squamous cell, and prostate carcinoma tissue sam-
ples and arrays, in addition to corresponding normal tissue, were ob-
tained from FolioBio (Columbus, OH). Metastatic melanoma arrays
were from Imgenex (San Diego, CA).
Cell Culture and Transfections
Human WM115 and WM266 melanoma cell lines, L cells, and
HeLa cells were purchased from American Type Culture Collection
(ATCC, Manassas, VA). WM115 is a VGP melanoma, and WM266
is a metastatic melanoma isolated from the same patient. The human
U343 glioma cell line was generously provided by A. Guha (University
of Toronto, Ontario, Canada), and the U251 glioma cell line was
generously provided by R. Bjervig (University of Bergen, Norway).
U343, U251, and L cells were cultured in Dulbecco modified Eagle
medium (DMEM; Invitrogen, Burlington, Ontario, Canada) sup-
plemented with 10% fetal bovine serum (FBS; Invitrogen). Human
WM115 and WM266 cells were cultured in modified Eagle medium
(Invitrogen) supplemented with 2 mM L-glutamine, Earle’s balanced
salt solution, and 10% FBS and were adjusted to contain 1.5 g/L
sodium bicarbonate, 0.1 mM nonessential amino acids and 1.0 mM
sodium pyruvate. All cell lines were cultured in 100 U/ml penicillin
and 100 mg/ml streptomycin and maintained at 37°C in a humidified
atmosphere of 5% CO2.
NCAD- or ECAD-expressingmouse L cells were previously described
[6]. Lipofectamine Plus transfection reagent (Invitrogen) was used to
transfect WM115, WM266, U343, and HeLa cells with NCAD con-
structs and to transfect U251 cells with V5-tagged furin complementary
DNA (cDNA) [34]. For the selection of stable cell lines, cells were seeded
in complete DMEM containing 600 μg/ml of Geneticin (Invitrogen),
the day after transfection. Colonies were isolated and examined for
proNCAD-myc or myc-tagged mock vector, or proNCAD-GFP, or
GFP-tagged mock vector by immunocytochemistry.
Constructs
Mutant proNCAD myc- or GFP-tagged cDNA were previously de-
scribed [6]. V5-tagged furin cDNAwas cloned into the pIRES2-EGFP
vector [34].
Antibodies and Reagents
The following primary antibodies were used for immunoblots, immu-
nocytochemistry, and immunohistochemistry: rabbit affinity-purified
polyclonal anti-NCAD cytoplasmic domain, and anti-proN [6] (gen-
erated in D.R.C. laboratory), rat monoclonal anti-NCAD extracellular
domain (NEC2) (Dr. M. Takeichi, RIKEN, Japan), mouse monoclonal
anti-GFP (BD Biosciences, Mississauga, Ontario, Canada), mouse
monoclonal anti-myc (clone 9E10; Sigma-Aldrich, Oakville, Ontario,
Canada), rabbit polyclonal anti-furin (generated in N.G.S. laboratory),
mouse monoclonal anti-ERK, mouse monoclonal anti-tubulin, rabbit
polyclonal anti-nestin, mouse monoclonal anti–β-catenin, mouse anti-
actin, and fluorescent-conjugated secondary antibodies were from
Millipore (Billerica, MA). Mouse anti–Na+/K+-ATPase was from Abcam
(Cambridge, MA).
Fluorescence mounting medium (DAKO, Burlington, Ontario,
Canada) was used to mount coverslips on glass slides. Factor Xa and
5-fluoro-2′-deoxyuridine (FDU) were from Sigma-Aldrich Canada Ltd.
Immunoblot Analysis
For protein extraction, subconfluent monolayers were washed with
PBS, dissociated using 2 mMEDTA in PBS (as previously mentioned),
and pelleted at 1000 rpm for 5 minutes. Lysates were obtained using
RIPA lysis buffer (150 mM NaCl, 20 mM Tris-HCl, pH 7.5, 1%
NP-40, 1% Triton X-100) with Complete Mini protease inhibitors
(Roche Diagnostics, Laval, Quebec, Canada) on ice for 30 minutes.
After cell lysis, samples were centrifuged for 15 minutes at 15,000 rpm,
and the supernatants were transferred to clean tubes. Protein concen-
tration was determined using the Lowry assay (Bio-Rad DC protein
assay, Mississauga, Ontario, Canada), and samples were run on a 4%
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to 15% linear gradient SDS-PAGE gel (Bio-Rad), transferred to nitro-
cellulose, membrane-blocked with 5% milk protein, and incubated
overnight with primary antibodies at 4°C. Blots were then incubated
with HRP-conjugated secondary antibodies, and routine washes were
carried out. Blots were developed with the chemiluminescence system
(Pierce Biotechnology, Rockford, IL). Alternatively, for signal quan-
tification, the chemifluorescence kit (Pierce Biotechnology) and the
Storm Imager were used. An independent loading control (actin or
Na+/K+-ATPase) was used to normalize signals analyzed by densitome-
try. Densitometric analysis was carried out using the Image J software
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(National Institutes of Health, Bethesda, MD). Bands were boxed, and
background signal was subtracted from their relative intensities. Inten-
sity values were normalized to reference values (loading control).
Cell Surface Biotinylation
Subconfluent monolayers were washed three times with ice-cold PBS
containing 2 mM MgCl2 and incubated with 0.2 mg/ml EZ-Link
NHS-SS-Biotin (Pierce Biotechnology) solution in PBS for 30 minutes
at 4°C to inhibit endocytosis. Excess biotin was quenched by washing
three times with ice-cold TBS (25 mM Tris-HCl, pH 8.0, 150 mM
NaCl, 2 mM MgCl2, and 2 mM CaCl2) followed by three washes
with ice-cold PBS. Cells were scraped off the plate with 0.5 ml of RIPA
buffer, and lysis was carried out as previously mentioned, followed by
protein concentration determination of lysate supernatants. Immuno-
Pure Immobilized Streptavidin beads (Pierce Biotechnology) were
added to the total protein, and the volume was brought up to 0.5 ml
with RIPA buffer. Binding of biotinylated proteins to streptavidin
beads occurred during a 2-hour incubation at 4°C, with gentle rocking.
Streptavidin beads were pelleted (13,000 rpm at 4°C), the supernatant
was discarded, and beads were washed with 1 ml of RIPA buffer three
times. The supernatant from the last wash was discarded and 2× SDS
sample buffer containing 100 mM DTTwas added to dissociate the
biotinylated proteins from the streptavidin beads through reduction
of the disulfide bond in the biotin molecule. Samples were run on
SDS-PAGE gels, and immunoblot analysis was carried out as outlined
previously mentioned. Anti-NCAD cytoplasmic antibody was used to
detect total NCAD protein (mature and precursor), anti-proN anti-
body was used to detect proNCAD, anti–Na+/K+-ATPase was used
as a loading control, and anti-ERK was used as a cell surface biotinyla-
tion control.
Immunocytochemistry
Cells were plated onto poly-L-lysine–coated coverslips in supple-
mented DMEM (see previous discussion). Cells were fixed in 4%
paraformaldehyde, permeabilized in 0.3% Triton X, PBS, and blocked
in 5% BSA, 5% goat serum, PBS. Cells were then incubated for 1 hour
in primary antibody diluted in 1% BSA, 0.02% Triton X, PBS, fol-
lowed by a 40-minute incubation in fluorescent-conjugated secondary
antibodies. Three washes with PBS were performed before fixation,
as well as after each step. Coverslips were mounted and examined
by confocal laser microscopy using the Zeiss LSM 510 microscope
(Carl Zeiss Canada, Ltd., Toronto, Canada) with the Zen image ac-
quisition software and a 60× oil immersion objective. Images were
acquired in the same plane of focus between comparisons.
Live cell staining was carried out by incubating cells plated on
coverslips with primary antibody diluted in medium without serum
at 4°C for 1 hour. The cells were washed with PBS and fixed in
3.7% paraformaldehyde. After washes with PBS, cells were incubated
with fluorescent-conjugated secondary antibody diluted in 1% BSA,
0.02% Triton X, PBS, for 40 minutes at room temperature. Cover-
slips were then mounted and examined as previously mentioned.
Immunohistochemistry
Paraffin-embedded tissue was deparaffinized and rehydrated. The
antigen retrieval solution consisted of citric acid pH 6. The tissue
was subsequently washed with PBS for 5 minutes, blocked in PBS
containing 10% FBS and 0.5% Triton X-100 for 90 minutes, and
incubated with primary antibody in blocking solution overnight at
4°C in a humidified chamber. Sections were then washed three times
in PBS, incubated in secondary antibody in blocking solution for
90 minutes at room temperature in a humidified chamber, and
washed two times in PBS. Slides were mounted and examined by con-
focal laser microscopy using the Zeiss LSM 510 microscope.
Cell Aggregation Assays
Aggregation assays were carried out as previously described [35].
Briefly, monolayer cultures were treated with 2 mM EDTA in PBS
for 5 minutes at 37°C. The cells were then washed gently in HCMF
(HEPES-buffered Ca2+-Mg2+-free Hank’s balanced salt solution) sup-
plemented with 1 mM CaCl2 and 1% BSA for 30 minutes at 37°C to
dissociate the monolayer into single cells while leaving cadherins in-
tact on the cell surface. After cell dissociation, 5 × 105 cells per well
were transferred to 24-well low-adherent dishes (VWR, Mississauga,
Ontario, Canada), and brought up to a final volume of 0.5 ml of
Figure 1. ProNCAD is expressed on the surface of invasive tumor cells. (A) Western blot analysis of NCAD levels in U343 and U251
glioma cells and in WM115 and WM266 melanoma cells using an NCAD cytoplasmic antibody. Anti-actin immunoblot is shown as
an independent loading control. Results were quantified by densitometric analysis. (B) Left panel: Western blot analysis of cell sur-
face biotinylated proteins from U343 and U251 cells. A cell surface biotinylation assay was carried out to determine the proportion
of proNCAD on the surface of U343 and U251 cells. Experiments were carried out with 90 or 60 μg of total protein, and NCAD cyto-
plasmic and proN antibodies were used to detect total NCAD and specifically proNCAD, respectively. Anti–Na+/K+-ATPase blot is shown
as an independent loading control for both total cell lysates and biotinylated fractions. Anti-ERK blot is shown as a control for surface
biotinylation. The proportion of surface to total proNCAD was determined by densitometry. Values are means ± SEM. *P < .01. Right
panel: Western blot analysis of cell lysates of WM115 and WM266 melanoma cells. NCAD cytoplasmic antibody detected levels of total
NCAD protein in the melanoma cells. The proN antibody specifically detected substantially higher levels of proNCAD in WM266 cells.
L cells overexpressing NCAD (LN cells) served as a positive control for properly processed NCAD. Anti-actin blot is shown as a loading
control. (C) Immunocytochemistry demonstrating intracellular localization of proNCAD in permeabilized tumor cells (top panels) and
substantial surface localization in U251 and WM266 nonpermeabilized (bottom panels), live tumor cells. Images were taken using
the Zeiss LSM 510 confocal microscope with the Zen image acquisition software and a 60× oil immersion objective. All cells were
visualized in the same plane of focus between comparisons. Bar, 10 μm. (D) Cell aggregation assay of glioma and melanoma cells
in the presence of calcium during a 40-minute time course. The number of single cells was counted during cell aggregation under a
light microscope, and the percentage of single cells during the aggregation assay was determined by the index Nt /N0, where Nt is the
total number of single cells after a certain incubation time and N0 is the total number of single cells at the initiation of incubation. Values
are means ± SEM. Results in each panel are representative of three independent experiments.
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HCMF containing 1% BSA with or without 1 mM Ca2+. The plates
were rotated at 80 rpm at 37°C for observation of aggregate formation
during a 40-minute time course. At t = 0 minute, t = 20 minutes, and
t = 40 minutes, 50 μl of the fixed aggregates was removed, placed on
a slide, covered with a coverslip, and examined by light microscopy.
The number of single cells was counted, and the percentage of single
cells during the aggregation assay was determined by the index Nt/N0,
where Nt is the total number of single cells after a certain incubation
time, and N0 is the total number of single cells at the initiation of
incubation. Where applicable, factor Xa (0.4 U/ml; Sigma) was added
before and after cell dissociation.
MTT Proliferation Assays
Cells were seeded in a 96-well plate at a density of 1000 cells per
well, and at 24-, 72-, and 120-hour time points, MTT (Sigma-Aldrich)
was added at a final concentration of 0.5 mg/ml, and the plate was in-
cubated at 37°C for 4 hours. The medium was then removed, 100 μl of
DMSOwas added per well, the plate was incubated at 37°C for 1 hour,
and the absorption was measured at 595 nm using a spectropho-
tometer. The optical density of the sample was subtracted from that
of the blank, and data were plotted versus time. An exponential growth
trend line was applied to the data points yielding the following equa-
tion: y(t) = y0e
kt, where y(t) is the optical density at 595 nm at time
point t, y0 is the optical density at t = 0 hour, k is the growth constant,
and t = time. The doubling time (td) was calculated using the equation
td = ln2 / k.
Wound Healing Migration Assays
To assess two-dimensional migration of tumor cell lines, 3 × 105 cells
were seeded in six-well culture dishes. Before plating in these dishes,
two parallel lines were drawn at the underside of the well with a Sharpie
marker, serving as fiducial marks for analysis of wound areas. The cell
monolayer was 100% confluent at the day of analysis. The growth me-
dium was first aspirated and replaced by calcium-free PBS to prevent
death of cells at the edge of the wound by exposure to high calcium
concentrations. Monolayers were disrupted with a parallel scratch
wound made perpendicular to the marker lines with a fine pipette
tip. Migration into the wound was observed using phase-contrast mi-
croscopy on an inverted microscope with the 5× objective. Images were
taken at regular time intervals of areas flanking the intersections of the
wound and the marker lines. The number of cells that migrated into
the wound was determined by marking wound edges at t = 0 hour on
the underside of the well and counting cells that migrated into the
wound at specified time points appropriate for each cell lines using
Northern Eclipse software 6.0 (EMPIX Imaging, Inc, Mississauga,
Ontario, Canada). Factor Xa was added at a concentration of 0.4 U/ml,
where applicable.
Invasion Assays
Three-dimensional collagen gel invasion assays. Confluent mono-
layers of tumor cell lines were dissociated, and spheroids were prepared
using the hanging drop method as previously described [36,37].
Spheroids were implanted into four-well culture dishes containing
0.5-ml aliquots of a collagen type I solution (Vitrogen 100; Cohesion,
Palo Alto, CA) using a Pasteur pipette. After hardening of the gel at
37°C for 60 minutes, the gel was overlaid with 0.5 ml of supplemented
DMEM. Cell invasion was assessed daily using an inverted phase-
contrast light microscope. The number of cells invading at increasing
distances away from the spheroid on day 5 after implantation was as-
sessed using a concentric grid system (Northern Eclipse 6.0; EMPIX
Imaging, Inc). Where applicable, factor Xa was added at 0.4 U/ml
during spheroid preparation and postimplantation into the medium
overlaying the collagen gel. In addition, where applicable, FDU
(Sigma-Aldrich) was added after implantation into the medium over-
laying the collagen gel at a concentration of 0.2 μM.
Boyden chamber invasion assays. To assess cellular invasion, 3 ×
105 cells were seeded on the upper chamber of Matrigel-coated mem-
branes (8 μm pore size; Millipore). Conditioned medium was made by
incubating NIH3T3 cells in DMEM with 0.1% bovine calf serum
and 50 μg/ml ascorbic acid for 24 hours and was applied to the bot-
tom chamber, serving as a chemoattractant. The cells were allowed to
invade the Matrigel substrate for 12 hours in the tissue culture incu-
bator. The cells were fixed by replacing the culture medium with 4%
formaldehyde in PBS for 15 minutes at room temperature. The cham-
bers were then rinsed with PBS and stained with 0.2% crystal violet
for 10 minutes followed by another series of rinses. The remaining
cells that did not migrate through the membrane pores were removed
with several cotton swabs from the upper chamber, and the number
of invaded cells was counted using an inverted microscope and a 4×
objective. Factor Xa was added at a concentration of 0.4 U/ml,
where applicable.
Small Interfering RNA
Predesigned, small interfering RNA (siRNA) oligos targeting two
different regions of the human furin sequence (nos. 105594 and
112945), glyceraldehyde 3-phosphate dehydrogenase, and Cy3-labeled
negative control no. 1 were purchased from Ambion (Austin, TX).
U343 cells were transfected with furin siRNA (80 nM), respectively,
using Lipofectamine Plus reagent (Invitrogen). Cells were used in ex-
periments 3 days after transfection.
Analysis of Furin Expression in Cell Lines and Tissues
RNA was extracted from human cell lines and frozen tissue sam-
ples using RNeasy mini kit (Qiagen, Missisauga, Ontario, Canada).
The RNeasy FFPE kit was used to extract RNA from paraffin-
embedded tissue samples. cDNA were prepared using the RevertAid
H Minus First Strand cDNA Synthesis Kit (Fermentas, Burlington,
Ontario, Canada).
Semiquantitative polymerase chain reaction (PCR) was carried out to
determine furin expression, and GAPDH was used as a normalizing
control. Real-time PCR was carried out to quantify furin expression
relative to hS14 expression, as previously described [38]. Primers are
listed in Table W1.
Statistical Analysis
Descriptive statistics were analyzed using GraphPad Prism 4. Mean,
SEM, and Student’s t-test were used to determine significant differences
between pairs. Comparisons of migrating and invading single cells and
comparisons of furin levels in human tissue samples were performed
using a parametric or nonparametric analysis of variance and Tukey
or Dunnett multiple comparison tests, respectively. P < .05 was con-
sidered significant.
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Figure 2. Cell surface expression of proNCAD decreases intercellular adhesion. (A) Schematic diagram of proNCAD protein with endog-
enous PC recognition site, and the engineered factor Xa cleavage site. Tryptophan at position 2 is in bold. (B) Immunocytochemistry of
U343, WM115, and WM266 cells stably transfected with mutant proNCAD fused to c-myc (proNCAD-myc) or GFP tags (proNCAD-GFP),
or mock vectors, demonstrating colocalization of mutant proNCAD with c-myc and GFP, respectively. Images were taken using the Zeiss
LSM 510 confocal microscope with the Zen image acquisition software and a 60× oil immersion objective. All cells were visualized in
the same plane of focus between comparisons. Bar, 10 μm. (C) Cell aggregation assay of mutant proNCAD-transfected U343 cells or
mock-transfected cells, with or without factor Xa treatment. The number of single cells was counted during cell aggregation under a
light microscope, and the percentage of single cells during the aggregation assay was determined by the index Nt /N0, where Nt is the
total number of single cells after a certain incubation time and N0 is the total number of single cells at the initiation of incubation. Results
are representative of three independent experiments and values are means ± SEM. Bar, 50 μm.
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Results
Human Glioma and Melanoma Cells Express Cell
Surface ProNCAD
We previously observed that during early development, nonadhesive
precursor NCAD (proNCAD) is on the surface of immature neurons
(unpublished results), presumably facilitating the “slipping” of mem-
branes past one another. NCAD is also a major CAM during tumori-
genesis, as it is expressed on the surface of various types of tumors. The
migration and invasion of tumor cells may be considered to be analo-
gous to the motility of membranes during neurite outgrowth; therefore,
we hypothesized that changes in NCAD-mediated adhesion due to
surface proNCAD expression may be important during tumor progres-
sion [6]. It is conceivable that the correlation observed between
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up-regulation of NCAD during tumor progression and increased
tumor cellular motility [19–21] is largely due to the aberrant expression
of cell surface nonadhesive proNCAD, decreasing cell-cell adhesion and
promoting migration and invasion.
To test the role of proNCAD in tumorigenesis, we used two differ-
ent tumor models in which NCAD expression plays an important role
during tumor progression. We investigated the cellular distribution and
functional state of the NCADmolecule at the cell surface in melanoma
and malignant glioma. Melanoma is a tumor model that undergoes
an ECAD-to-NCAD transition whereby ECAD expression is down-
regulated in VGP cells and NCAD expression is upregulated and main-
tained during cancer progression [15,16]. Malignant glioma is a tumor
model that exhibits persistence of NCAD during malignant progres-
sion, and compared with normal brain tissue, an increase in NCAD
expression has been shown in malignant glioma [33].
We made use of melanoma cell lines representing different stages of
transformation. WM115 was derived from VGP melanoma at the pri-
mary tumor site, and WM266 was derived from metastatic melanoma
at a secondary site from the same patient. We also used the U343 and
U251 glioma cell lines, isolated from malignant gliomas. U251 cells are
more invasive in a collagen gel implantation assay than U343 cells
(Figure W1A). Because these cell lines exhibit significantly different
proliferation rates (please refer to Figure W6 and Table W2), we also
carried out the invasion assay in the presence of FDU, an antiprolifera-
tive agent to exclude the effect of proliferation in the assay, and our
results show that the difference in invasion between U251 and U343
cells is maintained (Figure W1B).
We first wanted to evaluate the levels of total NCAD in the glioma
and melanoma cell lines. To this end, we made use of an antibody
against the cytoplasmic domain of NCAD to detect total NCAD levels
in U343, U251, WM115, and WM266 cell lines by Western blot
analysis. We found that total NCAD levels were comparable in both
glioma cell lines (Figure 1A) and in both melanoma cell lines (Fig-
ure 1A). Using a previously characterized rabbit polyclonal antibody
specifically against the NCAD prodomain (anti-proN) [6], we next
investigated whether a proportion of the NCAD expressed at the cell
surface was unprocessed, in the nonadhesive precursor form. We car-
ried out cell surface biotinylation experiments where proteins at the
surface of cells were labeled with biotin and affinity purified using a
streptavidin resin and then analyzed by immunoblot analysis. Surpris-
ingly, we found a high proportion of proNCAD on the surface of highly
invasive U251 cells compared with the indolent U343 cells in cell
surface biotinylation experiments (Figure 1B). Similarly, expression of
proNCAD was estimated to be three times greater in metastatic
WM266 cells compared with VGP WM115 cells (Figure 1B). We also
examined the immunolocalization of proNCAD and found that it
could be detected intracellularly in permeabilized glioma and mela-
noma cells (Figure 1C , top panels). Under nonpermeabilizing condi-
tions, proNCAD was detected on the surface of U251 and WM266
cells and, to a lesser extent, on the surface of WM115 cells (Figure 1C ,
bottom panels) and coexisted with mature NCAD (Figure W2). Sur-
face proNCAD staining of U343 cells was negligible (Figure 1C , bottom
panels), in agreement with our immunoblot analysis.
Our results show that NCAD is an abundant component of mela-
noma and glioma cell lines and that proNCAD is highly expressed on
the surface of invasive U251 cells and metastaticWM266 cells. Because
proNCAD is nonadhesive, we would expect U251 and WM266 cells
to exhibit lower intercellular adhesive activity compared with U343 and
WM115 cells. To test differences in cellular adhesion between these cell
lines, we carried out cell aggregation assays. In these assays, cells were
dissociated while leaving cadherins intact at the cell surface, and aggre-
gation was monitored over time.We observed greater aggregation in less
invasive U343 glioma cells and in WM115 VGP melanoma cells com-
paredwith highly invasiveU251 cells andWM266metastaticmelanoma
cells, respectively (Figures 1D and W3). There was no aggregation in
the absence of calcium for all cell lines (data not shown). These results
suggest that higher levels of cell surface nonadhesive proNCAD corre-
late with less cell aggregation in the U251 and WM266 cell lines.
Overexpression of ProNCAD Promotes Glioma
and Melanoma Cell Motility
Our data demonstrate an inverse correlation between surface-
expressed proNCAD and adhesive behavior. Because NCAD expres-
sion correlates with increased motility and proNCAD lacks adhesive
function, we hypothesized that loss of adhesion due to aberrant surface
expression of proNCAD may serve as a mechanism for enhanced
motility in tumor cells, even in the presence of mature NCAD. To ad-
dress how proNCAD might influence invasion and metastasis in these
tumor cells, we engineered an NCAD construct (proNCAD) where the
endogenous consensus PC cleavage site [6,39] was replaced with a
serum coagulation factor Xa recognition site in the linker sequence
(Figure 2A). Glioma and melanoma cell lines were transfected with
mutant myc-tagged proNCAD and mutant GFP-tagged proNCAD,
respectively, and clones were selected and expanded. The expression
of mutant proteins at the surface of transfected cells was verified by
immunofluorescence. Myc and proNCAD colocalized extensively at the
plasma membrane of transfected glioma cells, and GFP and proNCAD
showed a similar localization in transfected melanoma cells (Figure 2B).
Figure 3. Cell surface expression of proNCAD promotes migration and invasion of tumor cells. (A) i. and ii. Wound healing assays were
carried out with mutant proNCAD- and mock-transfected U343 cells, WM115 cells, and WM266 cells, with or without factor Xa treatment.
Monolayers were disrupted by scraping with a fine pipette tip, and migration into the wound was monitored. The number of cells that
migrated into the wound was counted using Northern Eclipse software. Migration of U343 cells was quantified at 12 hours, migration of
both melanoma cells lines was quantified at 6 hours, and the results were plotted as a proportion of the number of mock-transfected cells.
Values are means ± SEM. Bar, 50 μm. *P < .01. (B) i. Three-dimensional collagen gel invasion assay. Spheroids of mutant proNCAD- and
mock-transfected U343 cells were implanted into a collagen matrix. Invasion was monitored and quantified by counting the number of cells
invading at increasing distances away from the spheroid using concentric grids spaced at 150 μm, where the edge of the spheroid was
designated as 0 μm. Results obtained on day 5 after implantation were plotted as a proportion of the number of mock-transfected cells.
Values are means ± SEM. Bar, 100 μm. ii. Boyden chamber invasion assay. Cell invasion was measured using a Boyden chamber assay.
Mutant proNCAD- and mock-transfected WM115 and WM266 cells were plated onto Matrigel-coated transwells. Cells that invaded to the
lower chamber were counted 12 hours after plating, and results are plotted as a proportion of the number of invadedmock-transfected cells.
Values are means ± SEM. *P < .01. Results in each panel are representative of three independent experiments.
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Cleavage of the prodomain by factor Xa was detected by immunoblot
analysis of total cell lysates or conditioned medium of transfected cells.
ProNCAD-myc levels were decreased on treatment with factor Xa
(Figure W4A), and cleavage did not compromise the integrity of the
mature protein (Figure W4B). Accumulation of the 17-kDa fragment
in the conditioned medium indicates specific cleavage of the mutant
prodomain by factor Xa (Figure W4C).
We investigated the effect of surface proNCAD expression on inter-
cellular adhesion by carrying out cell aggregation assays with the trans-
fected cells described previously. We found that cells transfected with
mutant proNCAD formed considerably smaller aggregates compared
with mock-transfected cells (Figure 2C). Treatment with factor Xa re-
stored cell-to-cell adhesion, resulting in aggregates comparable to those
observed with mock-transfected cells (Figure 2C ). Results were quan-
tified as percent of single cells over time, demonstrating low aggregation
for transfected cells and high aggregation for mock-transfected cells in
the presence or absence of factor Xa, as well as high aggregation of trans-
fected cells in the presence of Xa. Therefore, these data support the
notion that cell surface expression of proNCAD leads to a decrease
in cell-cell adhesion.
It is conceivable that decreased intercellular adhesion due to surface
expression of proNCAD would affect cellular motility. To examine the
role of proNCAD in cell motility, we performed a wound healing assay
in which confluent monolayers were disrupted by scraping with a fine
pipette tip, and migration of cells into the wound was monitored and
quantified over time. WM115 and WM266 cells transfected with
mutant proNCAD exhibited increased migration during a 6-hour
period compared with mock-transfected controls (Figure 3A). This ef-
fect was significantly decreased on treatment of proNCAD-transfected
cells with factor Xa (Figure 3A). The most dense cell monolayer was
observed with WM266 cells transfected with mutant proNCAD be-
cause these cells express both transfected and endogenous surface pro-
NCAD (Figure 3A). Similarly, U343 cells overexpressing mutant
proNCAD exhibited increased migration into the wound during a
12-hour period compared with mock-transfected cells, and this effect
was abolished by treatment with factor Xa (Figure 3A). Furthermore, to
show the direct involvement of proNCAD in cell migration, we carried
out migration assays using HeLa cells, a cell line lacking detectable ex-
pression of classic adhesion molecules, including NCAD (Figure W5A)
[40,41]. HeLa cells were transfected with mutant proNCAD or mock
construct, and experiments were carried out in the presence or absence
of factor Xa. Compared with mock-transfected HeLa cells, proNCAD-
transfected cells migrated 1.7 times more 10 hours after monolayers
were disrupted (Figure W5, B and C ). On addition of factor Xa, which
cleaves the prodomain at the engineered consensus site rendering the
NCAD molecule adhesive, we observed a significant decrease in migra-
tion (Figure W5, B and C).
Because the effect of cellular proliferation is not taken into account in
migration assays, we tested whether proNCAD expression affects pro-
liferation of transfected cells. We performed MTT proliferation assays
where the reduction of tetrazolium salt (MTT) in metabolically active
cells to a purple formazan product was quantified spectrophotometri-
cally, and doubling timeswere calculated. These assays yielded a doubling
time of ∼23 hours for both mock- and mutant proNCAD-transfected
U343 cells, ∼28 hours for both mock- and mutant proNCAD-transfected
WM115 cells, ∼26 hours for both mock- and mutant proNCAD-
transfected WM266 cells, and ∼24 hours for both mock- and mutant
proNCAD-transfected HeLa cells (Figure W6 and Table W2). There-
fore, although migration was quantified at time points far from the
doubling time of these cell lines, we can exclude the effect of growth
in this assay because proNCAD does not significantly alter the pro-
liferation rate of transfected cells.
The implication of proNCAD in cellular migration warranted the
investigation of its role in more complex cellular behaviors such as inva-
sion. To this end, cellular invasion was assessed using three-dimensional
collagen gel invasion assays and Boyden chamber invasion assays.
Spheroids of mutant proNCAD- or mock-transfected glioma cells were
prepared using the hanging drop method and implanted into a collagen
gel matrix in the presence or absence of factor Xa, and invasion was quan-
tified on day 5 using a phase-contrast light microscope and Northern
Eclipse software (Figure 3B). Compared with the control, transfection
with mutant proNCAD resulted in more than double the number of
U343 cells invading up to distances greater than 300 μm from the edge
of the spheroid. This effect was most pronounced at distances greater
than 300 μm, where there were nine-fold more proNCAD transfected
cells invading compared with control cells (Figure 3B). This effect was
reversed on treatment with factor Xa. Because the melanoma cell lines
did not form spheroids, Boyden chamber assays were carried out to assess
the effect of proNCADon invasion of melanoma cells. Cells were seeded
in the upper chamber of a Matrigel coated filter, and NIH3T3 condi-
tioned medium was used as a chemoattractant in the lower chamber.
Cells that invaded the Matrigel substrate were quantified 12 hours after
monolayer disruption using a light microscope. ProNCAD surface ex-
pression substantially increased invasiveness relative to the parental
WM115 and WM266 lines (Figure 3B). Treatment with factor Xa
reduced invasion to levels observed with parental lines. As mentioned
Figure 4. Migration and aggregation of U251 and U343 cells depends on furin expression. (A) Left panel: Semiquantitative RT-PCR was
carried out to evaluate expression of furin. GAPDH expressionwas used as a normalizing control. Right panel: Real-time PCRwas carried out
to quantify furin expression in these cells. The results are plotted as mRNA transcripts, normalized to human ribosomal protein S14. HeLa
cells were used as a positive control for furin expression. Each experiment was carried out in triplicate, and values are means ± SEM. (B) A
wound healing assay was carried out with mock-transfected cells or U251-furin cells. In addition, this assay was carried out with U343 cells
transfected with two different siRNAs targeting the furin sequence. The number of cells that migrated into the wound was counted using
Northern Eclipse software 6.0 (EMPIX Imaging, Inc). Bar, 50 μm. The presence of surface proNCAD was also detected in U343 and U251
transfected cells by immunocytochemistry under nonpermeabilizing conditions. Images were taken using the Zeiss LSM 510 confocal
microscope with the Zen image acquisition software and a 60× oil immersion objective. All cells were visualized in the same plane of focus
between comparisons. Bar, 10 μm. Migration assay results were quantified as number of migrated cells at 12 hours. Values are means ±
SEM. *P < .01. (C) A cell aggregation assay was carried out with the stably transfected glioma cells and siRNA-transfected cells. Cell
aggregation was monitored during a 40-minute period, and results were quantified as the percentage of single cells determined by the
index Nt /N0, where Nt is the total number of single cells after a certain incubation time and N0 is the total number of single cells at the
initiation of incubation. Values are means ± SEM. Bar, 50 μm. Results in each panel are representative of three independent experiments.
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above for migration assays, the effect of cellular proliferation is not taken
into account in invasion assays. However, we can exclude the effect of
growth in these assays because proNCAD does not significantly alter
the proliferation rate of transfected cells (Figure W6 and Table W2).
Collectively, our data demonstrate that inhibition of cell-to-cell ad-
hesion by surface-expressed proNCAD promotes malignant tumor
cell behaviors such as migration and invasion in glioma and mela-
noma cells.
Furin Is Differentially Expressed in Glioma Cells and
Determines the Extent of Cellular Migration
Classic cadherins are synthesized as inactive propeptide precursors,
which become functional mature proteins on posttranslational pro-
cessing. The subtisilin-like basic amino acid–specific PCs are a family
of Ca2+-dependent endoproteases, responsible for the activation of pre-
cursor proteins by cleavage at a consensus recognition site (Arg/Lys-
(X)n-Lys/Arg-Arg, n = 0, 2, 4, or 6) [42,43]. ProNCAD, like other
classic cadherins [44], has a consensus cleavage site for furin [6,44],
at the C-terminal end of the prodomain. Furin is one of the most
common and widely expressed PCs and processes precursor proteins
in the constitutive secretory pathway [45].
Because furin is a ubiquitously expressed PC and a putative convertase
that cleaves the precursor form of NCAD, we analyzed its expression in
the tumor cells predicting that differences in levels of this enzyme might
underlie the mechanism leading to surface expression of proNCAD. In-
terestingly, furin expression was lower in U251 cells relative to U343 cells
(Figure 4A). This differencewas quantified by quantitative real-time PCR
and found to be more than 30-fold less in U251 compared with U343
cells (Figure 4A). Low furin levels inU251 cells might explain proNCAD
surface expression in these cells because the immatureN-cadherin protein
would not be properly cleaved at the consensus site. High furin levels
would be expected to render tumor cells less invasive and more adhesive
to one another because N-cadherin would be properly cleaved.
Because we observed a marked difference in furin expression between
U251 and U343 cell lines, we predicted that altering the expression of
furin would affect the migration and aggregation behaviors of these cell
lines. To this end, we carried out knockdown experiments using siRNAs
specifically targeting furin and gain-of-function experiments where cells
were stably transfectedwith furin.U343 cells were successfully transfected
with siRNA targeting the furin sequence (Figure W7A), and an 80%
reduction of furin messenger RNA (mRNA) levels was demonstrated by
reverse transcription–polymerase chain reaction (RT-PCR; FigureW7, B
and C ). Furin siRNA did not affect PC7 or NCAD mRNA levels
(Figure W7B). In addition, GAPDH levels were not affected but were
reduced by a GAPDH-specific siRNA (Figure W7B). Immunocyto-
chemistry also demonstrated a reduction in furin levels in U343 cells
(FigureW7D), but there was no reduction in tubulin, nestin, or β-catenin
expression (FigureW7D). Knockdown of furin inU343 cells resulted in a
substantial increase in cell migration (Figure 4B) and a decrease in cell
aggregation (Figure 4C) comparedwith control cells. Knockdownof furin
also resulted in an increase in surface proNCAD levels under nonperme-
abilizing conditions (Figure 4B). In our gain-of-function studies, using a
bicistronic pIRES-EGFPvector expressing aC-terminallyV5-tagged furin,
transfected cells exhibited colocalization of furin immunoreactivity with
EGFP fluorescence (data not shown). Compared withmock transfections,
overexpression of furin in U251 cells resulted in a substantial decrease in
the number of migrated cells at 12 hours in a migration assay (Figure 4B)
and a decrease in surface proNCAD levels under nonpermeabilizing con-
ditions (Figure 4B).U251 cells transfectedwith furin aggregated to amuch
greater extent compared with control cells (Figure 4C). Because the effect
of cellular proliferation is not taken into account in these migration assays,
we tested whether siRNA transfections and furin expression affect the pro-
liferation of U343 andU251 cells, respectively.We performed proliferation
assays, which yielded a doubling time of ∼24 hours for U343 cells trans-
fected with control siRNA and furin-targeted siRNAs. Proliferation assays
testing U251 cells transfected with mock or furin constructs yielded
doubling times of 22.6 and 22.2 hours, respectively (Figure W6 and
TableW2), which were not significantly different. Thus, although migra-
tion was quantified at time points far from the doubling time of these cell
lines, we can exclude the effect of growth in this assay because neither furin
knockdown or overexpression significantly alters the proliferation rate of
transfected cells.
These results demonstrate that furin expression seems to inhibit
glioma cell migration by affecting cell-to-cell adhesion; conversely, lack
of furin expression leads to proNCAD accumulation at the cell surface,
a decrease in cell-to-cell adhesion, and an increase in cell migration.
ProNCAD Surface Expression and Furin Levels Correlate
with Human Tumor Grade
Together, our in vitro results demonstrate that, in highly invasive
and metastatic cancer cells, the NCAD protein is aberrantly processed
so that the precursor protein is expressed at the cell surface, rendering
these cells less adhesive, more migratory, and more invasive. Further-
more, our data suggest an important role for furin in posttranslational
processing of the precursor NCAD molecule.
Because N-cadherin is commonly expressed in several human tu-
mors, we investigated the clinical relevance of this phenomenon by
screening the expression of proNCAD and furin in a panel of human
epithelial derived tumors as well as in corresponding normal control
tissues. ProNCAD immunoreactivity was determined in paraffin-
embedded human tissue samples and demonstrated an extremely strong
direct correlation between tumor grade and proNCAD expression.
ProNCAD immunoreactivity was strikingly elevated in high-grade
glioma, melanoma, squamous cell carcinoma (SCC), breast carcinoma,
and prostate carcinoma (Figure 5A). ProNCAD expression was also
elevated in metastases of melanoma, SCC, breast carcinoma, and pros-
tate carcinoma (Figure 5A). Conversely, proNCAD expression was rela-
tively weak in low-grade tumors (glioma, grade 2; SCC, grade 2; breast
carcinoma, grade 1; prostate carcinoma, grade 2) and was negligible in
corresponding normal control tissues (Figure 5A). NCAD expression
was also verified by immunohistochemistry (data not shown).
We also examined furin levels in normal and cancerous human tis-
sues. Quantitative real-time PCR results revealed an overall decrease
in furin expression during tumor progression (Figure 5B). More spe-
cifically, there was a significant decrease in furin expression when com-
paring normal dermal tissue with primary melanoma or with metastatic
melanoma (Figure 5B). Similarly, there was a significant decrease in
furin expression when comparing normal squamous tissue with primary
SCC or with metastatic SCC (Figure 5B). There was also a significant
decrease in furin expression between normal breast tissue and primary
breast carcinoma or metastatic breast carcinoma (Figure 5B). We ob-
served a decrease in furin expression between normal prostate tissue
and primary prostate carcinoma, or metastatic prostate carcinoma (Fig-
ure 5B). Although proNCAD expression was high in gliomas, furin
levels remained relatively constant (Figure 5B), possibly because most
invasive cells quickly migrate out of the tumor core [26].
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Figure 5. Detection of proNCAD and furin expression in normal and cancerous human tissues. (A) Immunohistochemistry using the proN
antibody was performed on paraffin-embedded low-grade and high-grade human cancerous tissues as well as corresponding normal tis-
sues. Images were taken using the Zeiss LSM 510 confocal microscope with the Zen image acquisition software and a 60× oil immersion
objective. ProNCAD surface expression (red) is detected in high-grade glioma, malignant, and metastatic melanoma and high-grade and
metastatic squamous cell, breast, and prostate carcinomas. Bar, 10 μm. (B) Real-time PCR was carried out to quantify furin expression
in human cancerous tissues as well as in corresponding normal tissues. The results are plotted as mRNA transcripts, normalized to human
ribosomal protein S14. *P < .01. Each real-time PCR experiment was carried out in triplicate, and values are means ± SEM.
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In summary, we show that cell surface proNCAD potentiates inva-
siveness in indolent tumor cells. Furthermore, we provide very strong
evidence supporting the relevance of our findings in human primary
tumors and metastases. Together, our results support the conclusion
that during malignant transformation, the extent of tumor cell invasion
is determined by the ratio of surface expressed nonadhesive proNCAD
to functional NCAD (Figure 6).
Discussion
Destabilized cell contacts, cellular reorganization, and metastatic dis-
semination are all associated with changes in cell adhesion. NCAD is
a major CAM in normal physiology and during tumorigenesis, and it
possesses a range of adhesive strengths. However, this hierarchy of ad-
hesion is thought to be regulated solely by monomer-dimer ratios [46],
“overlapping” domains [47], clustering [48], and by mass amounts of
cadherin on cell surfaces. Persistence of the prodomain on the surface
of tumor cells has not been observed previously, and it is believed that
the N-terminal prodomain in classic cadherins is completely removed
by members of the PC family, resulting in a mature, adhesively com-
petent molecule at the cell surface [6–8,49]. However, we have ob-
served proNCAD on the surfaces of neurites in the developing brain
(unpublished results).
Figure 6. Proposed schematic diagram depicting surface cadherin expression during tumor progression. (A) Illustration of the current
dogma for tumors that undergo an ECAD-to-NCAD transition: Premalignant cells, which are held together by ECAD, undergo an ECAD-
to-NCAD transition. This allows exit of these cells from an “ECAD epithelium” and invasion into surrounding tissues, where malignant cells
are able to interact with mesenchymal cells such as fibroblasts through NCAD. (B) I. A modification of the dogma based on our results:
Premalignant cells associate with each other through ECAD-mediated adhesion. A switch from ECAD to a mixture of mature NCAD and
nonadhesive proNCAD gives rise to invasion of malignant cells into surrounding tissues. Cells comprising high-grade tumors and
corresponding metastases express relatively higher levels of surface proNCAD compared with low-grade tumors. II. Other tumors, such
as gliomas, exhibit persistence of NCAD in their component cells normally, aswell as in the highlymalignant state. A decrease in intercellular
adhesion due to surface proNCAD expression allows detachment from the main tumor mass and invasion of the brain parenchyma. Cells
comprising high-grade tumors express relatively higher levels of surface proNCAD compared with low-grade tumors but generally do not
metastasize out of the brain.
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We report here that during malignant transformation, the NCAD
molecule undergoes altered proteolytic processing. This results in a
mixture of NCAD molecular forms at the cell surface and functionally
enhances cellular migration and invasion. Our results show unequivocal
proNCAD labeling in a panel of high-grade human tumor tissues. This
correlates well with down-regulation of furin RNA levels for all tumors
examined except gliomas. In the total pool of cells in normal brain and
glioma tissues, we observed relatively constant levels of furin during
malignant progression. This may be explained by the fact that these
tumors are extremely heterogeneous and that samples were taken from
the tumor core, well after detachment and exit of tumor cells with the
highest migratory potential [26]. To date, the role of furin in tumori-
genicity has been controversial, as it is responsible for cleaving not just
proNCAD but numerous other substrates as well [48,50–52].
NCAD is fundamentally involved in other dynamic cellular systems.
For example, it is important for physiological invasion in various non-
neoplastic cells such as during neural growth cone extension [53–56], as
well as during gastrulation when cells invaginate to form the mesoderm
[53,57], and the migration of neural crest cells [58,59] over large dis-
tances during embryonic development. In the last two cases, an ECAD-
to-NCAD switch similar to that which takes place in tumor cells is
important for the invasive phenotype [53,57–59]. It is conceivable that
differentially processed cell surface NCAD plays an important function
in these physiological processes.
Other groups have shown that NCAD plays a role in tumor progres-
sion, typically in tumor cells that undergo a switch from ECAD to
NCAD. The current hypothesis in the field is that NCAD expres-
sion is sufficient to promote malignant cell transformation [19,21,
60–62]. Yet, this body of work does not shed light on the stages
of malignancy during tumor progression. We propose that whereas
NCAD activity promotes malignant transformation, nonadhesive sur-
face proNCAD determines the degree of cell invasiveness in later stages
of tumor progression. Thus, the switch from ECAD to NCAD is in
reality a switch to a mixture of NCAD molecules where only a certain
proportion is functionally adhesive.
Classic cadherins can exist in a weakly adhesive monomeric form,
or as dimers, which are strongly adhesive [35,63]. We speculate that
proNCAD may disrupt NCAD arrays emanating from juxtaposed cells
by intercalating between lateral dimers (Figure 6). It has been shown that
the prodomain of ECAD prevents dimer formation, and it has also been
shown that dominant-negative forms of cadherins with extracellular do-
main deletions prevent cadherin self-association. It is conceivable that by
altering cadherin molecular forms and/or composition at the cell sur-
face, the adhesive strength of nascent cell-cell contacts may be regulated,
allowing for fine-tuning of malignant intercellular connections.
In summary, down-regulation of CAMs is one manner by which cells
decrease functionally adhesive intercellular interactions. In many car-
cinomas, epithelial junctions are no longer detectable due to the loss
of close cell-cell contacts. Another way that intercellular adhesion can
be modulated, as we demonstrate here, is by surface expression of a
nonadhesive CAM. We provide insight into the mechanism by which
NCAD can promote both stable and dynamic cell-cell interactions,
and our work revises the current dogma of cadherin posttranslational
processing and surface expression. Perhaps differences in relative cell
adhesion, rather than absolute cadherin specificity, dictate cell sorting
and migration in vivo.
We speculate that differential expression of PC enzymes may also
be a common mechanism in many types of tumors to regulate cellular
motility as well as other malignant traits. In addition, precursor forms
of other types of cadherins at the cell surface may play a similar role in
tumor cell motility. Determining the major form of NCAD at the cell
surface may serve as a prognostic tool for the staging and progression
of malignant tumors. Furthermore, our work sheds light on putative
novel treatment strategies with the potential to attenuate the extensive
infiltration and metastatic spread by invasive tumor cells.
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Figure W1. U251 human glioma cells exhibit extensive invasion
compared with U343 glioma cells in a three-dimensional assay. (A)
Spheroids of U343 and U251 glioma cells were implanted into a
type I collagen matrix. The relative invasion distance was measured
on days 1 and 5 after implantation using Northern Eclipse software.
(B) Spheroids of U343 and U251 glioma cells were implanted into a
type I collagenmatrix in the presence of 0.2 μMFDU antiproliferative
agent to exclude the effect of proliferation on invasion. Invasion was
measured on days 1 and 5 after implantation. Results in each panel
are representative of three independent experiments, and values are
means ± SEM.
Table W2. Doubling Times of Cell Lines Used in the Study.







U251 wt 22.65 0.45








Figure W2. Mature NCAD and proNCAD protein coexist on the cell surface. Immunocytochemistry demonstrating localization of NCAD,
detected with NEC2 antibody, and localization of proNCAD, detected with proN Ab, in permeabilizedWM115 andWM266 melanoma cells.
Figure W3. Aggregation of tumor cells. Aggregation assay of glioma
and melanoma cells, in the presence of calcium, demonstrating
more extensive aggregation of U343 and WM115 cells compared
with U251 and WM266 cells. Bar, 50 μm. Images are representative
of three independent experiments.
Figure W4. Cleavage by factor Xa does not compromise the integrity of mature NCAD. Western blot analysis of total cell lysates of
mutant proNCAD-myc or mock-transfected U343 cells (U343-m, U343-proNCAD) demonstrates that proNCAD-myc levels are decreased
to background on treatment with the specific protease, factor Xa, and that cleavage with factor Xa does not compromise the integrity of
the mature protein. (A) ProNCAD is detected with the proN antibody, and (B) both proNCAD and the mature protein are detected with
the NCAD cytoplasmic antibody. (C) Western blot analysis of conditioned medium collected from proNCAD- or mock-transfected cells
demonstrates specific cleavage of the mutant profragment as an accumulation of the profragment in the medium due to treatment with
factor Xa. L cells transfected with mutant proNCAD-myc (L-proNCAD) served as a positive control for the detection of unprocessed
NCAD (proNCAD) and proNCAD processed by factor Xa. Results are representative of three independent experiments.
Figure W5. Expression of proNCAD in the absence of NCAD promotes migration. (A) Western blot analysis of cell lysate from HeLa and
U251 cells, immunoblotted with anti-NCAD antibody or anti-actin antibody, demonstrating that HeLa cells do not express NCAD. (B) To
demonstrate the direct involvement of proNCAD in cell migration, wound healing assays were carried out with mutant proNCAD- and
mock-transfected HeLa cells, which lack NCAD expression. Experiments were carried out in the presence or absence of factor Xa, whereby
factor Xa cleaves the prodomain of proNCAD rendering the molecule adhesive. Monolayers were disrupted by scraping with a fine pipette
tip, and migration into the wound was monitored. The number of cells that migrated into the wound was counted using Northern Eclipse
software. Migration of HeLa cells was quantified at 10 hours, and (C) results were plotted as a proportion of the number ofmock-transfected
cells. Bar, 50 μm. Results are representative of three independent experiments, and values are means ± SEM. *P < .05.
Figure W6. MTT proliferation assays. (A) MTT proliferation assays were carried out on U343-mock, U343-proNCAD, WM115-mock,
WM115-proNCAD, WM266-mock, WM266-proNCAD, U251 wt, U343 wt, U343-ctl-siRNA, U343-furin-siRNA#1, U343-furin-siRNA#2,
U251-mock, U251-furin, HeLa-mock, and HeLa-proNCAD cell lines. Followed by treatment of cells with MTT, the absorbance of reduced
MTT was assayed on days 1, 3, and 5, using a spectrophotometer at a wavelength of 595 nm. Data are plotted as the absorption at 595 nm
versus time (h). Results in each panel are representative of three independent experiments. *P < .05.
Figure W7. Furin siRNA results in 80% knockdown of this convertase in U343 cells. Knockdown experiments using two different siRNAs
(Ambion) specific for furin (furin siRNA#1 and furin siRNA#2) were carried out in glioma cells. Cells were successfully transfected with siRNA
(A), and RT-PCR demonstrated an 80% reduction of furin mRNA levels in U343 cells (B and C). RT-PCR results are representative of three
independent experiments, and values are means ± SEM. *P < .01. Furin siRNAs did not affect PC7 or NCAD mRNA levels (B). In addition,
GAPDH levelswerenot affectedby furin siRNAsbutwere reducedby aGAPDH-specific siRNA (B). Immunocytochemistry alsodemonstrateda
reduction in furin levels in U343 cells, but there was no reduction in tubulin, nestin, or β-catenin expression (D). Bar, 10 μm.
